Valneva's Chikungunya Vaccine Faces FDA Setback, Long-Term Data Awaited
Valneva, the French biotech company, is set to release its long-term data on November 6, which could potentially restore investors' confidence. Meanwhile, the company faces challenges following the FDA's suspension of its Chikungunya vaccine license due to serious adverse effects.
In August, the FDA suspended the license for Valneva's Chikungunya vaccine, IXCHIQ, due to serious adverse effects. These included over 20 severe cases, 21 hospitalizations, and three deaths. Despite this setback, Valneva projects vaccine sales of 170-180 million euros for 2025 and aims for profitability by 2027. The global Chikungunya vaccine market is valued at over 500 million USD, with the travel segment worth 300-400 million USD.
Valneva's vaccine has shown promising results, with 95% of trial participants maintaining protective antibodies against Chikungunya four years after a single vaccination. This long-lasting immunity was observed in adults over 65, matching the protection seen in younger participants. The company has strategic partnerships with the Serum Institute of India and the Instituto Butantan to expand its market reach. Currently, IXCHIQ remains licensed in Europe, Canada, the UK, and Brazil.
As of October 2025, investor sentiment towards Valneva is divided. Some analysts see the sharp drop after the FDA setback as an attractive entry point, citing the promising Lyme vaccine pipeline. However, the stock is considered high-risk, and shareholders are advised to take urgent action ahead of the Q3 figures on November 20. Valneva has a cash position of 161 million euros. The upcoming data release on November 6 could potentially influence investors' decisions.
Read also:
- Information and Training Resource for FIFRA Section 18 Emergency Exemption Program – a program offering details on the process and requirements for expedited review and approval of pesticide products during emergency situations.
- Sanatorium in Sochi, Lazarev, has witnessed a lack of incoming patient applications.
